Effect and Mechanism of Dexmedetomidine on Inhibiting Proliferation, Migration and Invasion of Ovarian Cancer Cell Strain SKOV3

Abstract

To investigate the effect and mechanism of dexmedetomidine on SKOV3 proliferation, migration and invasion in ovarian cancer cell strains and the effect on high mobility group protein A2 expression. Western blot was used to detect the protein expression of high mobility group protein A2 in SKOV3 ovarian cancer cells; control group (without any treatment), (dexmedetomidine group 100 ng/ml was treated for 24 h), si-control group (transfection with si-control), si-high mobility group protein A2 group (transfection with si-high mobility group protein A2), dexmedetomidine+plasmid cloning deoxyribonucleic acid group (after transfection with plasmid cloning deoxyribonucleic acid group followed by dexmedetomidine 100 ng/ml treated for 24 h), dexmedetomidine+plasmid cloning deoxyribonucleic acid group-high mobility group protein A2 group (after transfection with plasmid cloning deoxyribonucleic acid-high mobility group protein A2 followed by dexmedetomidine 100 ng/ml treated for 24 h), were all transfected into SKOV3 cells using Lipofectamine; the proliferation of cells was detected by methyl thiazolyl tetrazolium assay; cell migration and invasion were detected by transwell assay; high mobility group protein A2 expression was measured by quantitative reverse transcription-polymerase chain reaction. The proliferation, migration and invasion of SKOV3 cells treated with dexmedetomidine were significantly down-regulated and high mobility group protein A2 expression was significantly down-regulated compared with the control group (p<0.05); knockdown of high mobility group protein A2 significantly inhibited SKOV3 cell proliferation, migration and invasion and overexpression of high mobility group protein A2 reversed the inhibitory effects of dexmedetomidine on ovarian cancer cell proliferation, migration and invasion. Dexmedetomidine can inhibit the proliferation, migration and invasion of ovarian cancer cells SKOV3 and the mechanism may be related to the direct down-regulation of high mobility group protein A2, which will provide a theoretical basis for dexmedetomidine treatment of ovarian cancer.